Report: Heart failure market set to reach $16bn by 2026

The heart failure market is expected to witness a compound annual growth rate of 15.7%, from $3.7bn in 2016 to $16.1bn by 2026, according to a report by GlobalData.

Titled ‘PharmaPoint: Heart Failure – Global Drug Forecast and Market Analysis to 2026’, the report covers the heart failure market of seven major markets such as the US, France, Germany, Italy, Spain, the UK and Japan.

An increase in uptake of Novartis’ Entresto is expected to be the major factor driving growth in the market. The launch of other heart failure therapies such as Amgen and Cytokinetics’ omecamtiv mecarbil, along with a rise in the prevalence of chronic heart failure and acute heart failure cases are also expected to improve market growth.

Existing heart failure therapies have been effective in slowing the progression of the disease and reducing mortality and morbidity. The success of these therapies, however, is mostly limited to the reduction of ejection fraction (HF-REF), explains Elizabeth Hamson, PhD, Healthcare Analyst for GlobalData.

These therapies have demonstrated only moderate benefits in heart failure with preserved ejection fraction (HF-PEF).

"As HF-PEF cases increase, pharmaceutical companies have an opportunity to develop therapies targeting the condition."

Pharmaceutical companies mostly focus on HF-REF therapies as they are also prescribed for the HF-PEF condition, despite the lack of clinical evidence.

As HF-PEF cases increase, pharmaceutical companies have an opportunity to develop therapies targeting the condition.

Novartis’ Entresto is the first-in-class angiotensin receptor-neprilysin inhibitor targeting HF-REF. The company is conducting late-stage trials in HF-PEF patients.

The report anticipates further label extensions of Entresto for treating HF-PEF for approval in 2020. If approved, the drug will fulfil a major unmet need in the market and help Novartis penetrate the heart failure market.

Treatment options for patients with multiple comorbidities such as renal impairment still remain unfulfilled, although the FDA approval of potassium-binding agents may help in meeting this unmet need to a certain extent.